341 related articles for article (PubMed ID: 16642939)
1. [Intermittent intravenous immunoglobulin infusion prevented relapses in patients with remission-exacerbation type chronic inflammatory demyelinating polyradiculoneuropathy].
Kanda F; Sekiguchi K; Oishi K; Hamaguchi H; Mitsui S; Kobessho H; Higuchi M; Shirafuji T; Ishihara H
Rinsho Shinkeigaku; 2006 Mar; 46(3):236-8. PubMed ID: 16642939
[TBL] [Abstract][Full Text] [Related]
2. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy.
Boërio D; Créange A; Hogrel JY; Guéguen A; Bertrand D; Lefaucheur JP
J Neurol Sci; 2010 May; 292(1-2):63-71. PubMed ID: 20219211
[TBL] [Abstract][Full Text] [Related]
3. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
Broyles R; Rodden L; Riley P; Berger M
Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.
Lopate G; Pestronk A; Al-Lozi M
Arch Neurol; 2005 Feb; 62(2):249-54. PubMed ID: 15710853
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.
Hughes RA
Expert Rev Neurother; 2009 Jun; 9(6):789-95. PubMed ID: 19496683
[TBL] [Abstract][Full Text] [Related]
6. Different types of chronic inflammatory demyelinating polyneuropathy have a different clinical course and response to treatment.
Jann S; Beretta S; Bramerio MA
Muscle Nerve; 2005 Sep; 32(3):351-6. PubMed ID: 16003765
[TBL] [Abstract][Full Text] [Related]
7. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.
Latov N; Deng C; Dalakas MC; Bril V; Donofrio P; Hanna K; Hartung HP; Hughes RA; Merkies IS; van Doorn PA;
Arch Neurol; 2010 Jul; 67(7):802-7. PubMed ID: 20457948
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and availability of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy].
Iijima M; Koike H; Sobue G
Nihon Rinsho; 2012 Apr; 70(4):715-21. PubMed ID: 22568158
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin.
Choudhary PP; Hughes RA
QJM; 1995 Jul; 88(7):493-502. PubMed ID: 7633875
[TBL] [Abstract][Full Text] [Related]
10. Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP.
van Doorn PA; Kuitwaard K; Jacobs BC
J Peripher Nerv Syst; 2011 Jun; 16 Suppl 1():38-40. PubMed ID: 21696496
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.
Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R
Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749
[TBL] [Abstract][Full Text] [Related]
12. Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement.
Kokubun N; Sada T; Yuki N; Okabe M; Hirata K
Eur Neurol; 2013; 70(1-2):65-9. PubMed ID: 23796651
[TBL] [Abstract][Full Text] [Related]
13. Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy.
Harbo T; Andersen H; Jakobsen J
Muscle Nerve; 2009 Apr; 39(4):439-47. PubMed ID: 19229876
[TBL] [Abstract][Full Text] [Related]
14. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy.
Hughes RA
Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S32-6. PubMed ID: 12690659
[TBL] [Abstract][Full Text] [Related]
15. Dose of intravenous immunoglobulins in chronic inflammatory demyelinating polyneuropathy.
Rajabally YA; Seow H; Wilson P
J Peripher Nerv Syst; 2006 Dec; 11(4):325-9. PubMed ID: 17117941
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of intravenous immunoglobulin in CIDP.
Vucic S; Black K; Baldassari LE; Tick Chong PS; Dawson KT; Cros D
Clin Neurophysiol; 2007 Sep; 118(9):1980-4. PubMed ID: 17604689
[TBL] [Abstract][Full Text] [Related]
17. Long-term evolution of anti-ganglioside antibody levels in patient with chronic dysimmune neuropathy under IVIg therapy.
Matà S; Borsini W; Caldini A; De Scisciolo G; Piacentini S; Taiuti R
J Neuroimmunol; 2006 Dec; 181(1-2):141-4. PubMed ID: 17023053
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial.
Nobile-Orazio E; Cocito D; Jann S; Uncini A; Beghi E; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Macchia R; Cavaletti G; Giannini F; Sabatelli M;
Lancet Neurol; 2012 Jun; 11(6):493-502. PubMed ID: 22578914
[TBL] [Abstract][Full Text] [Related]
19. [Treatment's initiation in chronic inflammatory demyelinating polyradiculopathy (CIDP)].
Uzenot D; Azulay JP; Pouget J
Rev Neurol (Paris); 2007 Sep; 163 Spec No 1():3S68-76. PubMed ID: 18087233
[TBL] [Abstract][Full Text] [Related]
20. Childhood acute and chronic immune-mediated polyradiculoneuropathies.
Rabie M; Nevo Y
Eur J Paediatr Neurol; 2009 May; 13(3):209-18. PubMed ID: 18585069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
